2020
DOI: 10.1002/hep.30924
|View full text |Cite
|
Sign up to set email alerts
|

Tumor‐Derived Peptidoglycan Recognition Protein 2 Predicts Survival and Antitumor Immune Responses in Hepatocellular Carcinoma

Abstract: Background and Aims Hepatocellular carcinoma (HCC) is linked to immunosuppression. Relieving immunosuppression has been an attractive strategy to improve the efficacy of cancer immunotherapy. Peptidoglycan recognition protein 2 (PGLYRP2) is a pattern recognition receptor which is specifically expressed in liver and implicated in the regulation of innate immunity and immunosurveillance. However, the role of hepatic PGLYRP2 in modulating immune responses against HCC remains to be investigated. Approach and Resul… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
24
0

Year Published

2020
2020
2024
2024

Publication Types

Select...
6
3

Relationship

3
6

Authors

Journals

citations
Cited by 29 publications
(25 citation statements)
references
References 35 publications
1
24
0
Order By: Relevance
“…Previous evidence has shown that PGLYRP2 is overexpressed in hepatocellular carcinoma (HCC) cells and can significantly strengthen the anti-tumor immune response in mice. Hence, tumor-derived PGLYRP2 is considered as a novel biomarker for HCC, and its potential in detecting cancer immunity and designing immunotherapies is highlighted [ 14 ]. In addition, PGLYRPs can regulate the sensitivity to inflammatory diseases.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Previous evidence has shown that PGLYRP2 is overexpressed in hepatocellular carcinoma (HCC) cells and can significantly strengthen the anti-tumor immune response in mice. Hence, tumor-derived PGLYRP2 is considered as a novel biomarker for HCC, and its potential in detecting cancer immunity and designing immunotherapies is highlighted [ 14 ]. In addition, PGLYRPs can regulate the sensitivity to inflammatory diseases.…”
Section: Discussionmentioning
confidence: 99%
“…Through hydrolyzing the amide bond between the N-acetylmuramic acid and L-Ala, PGLYRP2 separates the cross-linked bacterial peptidoglycans (PGN) and thus digests them into fragments. It is reported that PGLYRP2 is functional in tumor development, immune response in tumor microenvironment, infectious diseases, inflammatory responses and brain development [ 2 4 ]. To date, no studies have described the profile of PGLYRP2 in the case of SLE.…”
Section: Introductionmentioning
confidence: 99%
“…Luciferase assays were performed as previously described (Yang et al, 2020). Briefly, HEK293T cells were transfected with control 5′ UTR, full-length, SL1 alone, or SL1-deleted SARS-CoV-2 5′ UTR luciferase reporter plasmid using FuGENE Transfection Reagent (Promega).…”
Section: Luciferase Assaymentioning
confidence: 99%
“…Here, we presented a safe and effective NKM therapy for potential cancer adjuvant treatment and cancer prevention. We characterized the composition of our NKM cells and investigated the cytotoxicity in vitro and in vivo, and the results showed that they were signi cantly cytotoxic to K562 cells or hepatocellular carcinoma cells [36]. Although NKM therapy may not be as e cient as pure NK therapy, due to its ease of operation and safety (less immune-related side effects were found), we believed that NKM therapy is a su cient treatment for cancer adjuvant therapy, especially in combination with surgery to improve the immune response and eliminate residual cancer cells.…”
Section: Discussionmentioning
confidence: 99%